DeBartolo Family Personalized Medicine Institute, Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Department of Genetics, Stanford University, Stanford, California, USA.
Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13.
and polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimipramine). Evidence is presented for and genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for and Genotypes and Dosing of Tricyclic Antidepressants.
和 多态性影响三环类抗抑郁药 (TCAs) 的暴露、疗效和安全性，一些药物仅受 CYP2D6 影响（例如，去甲替林和去甲丙咪嗪），而另一些药物则同时受多种酶影响（例如，阿米替林、氯米帕明、多塞平、丙咪嗪和三甲丙咪嗪）。有证据表明 和 基因型指导的 TCAs 剂量。本文是对 2012 年临床药物遗传学实施联盟 (CPIC) 关于 和 基因型与三环类抗抑郁药剂量的指南的更新。
